Amarin Corp Plc (AMRN)

Price$15.24

Value ScoreB

Growth ScoreD

Momentum ScoreC

Favorite Metrics

Price vs S&P 500 (26W)-17.28%

Price vs S&P 500 (4W)2.20%

VGM Score53.69

Market Capitalization$312.60M

All Metrics

P/CF (Annual)46.46x

Book Value / Share (Quarterly)$21.42

P/TBV (Annual)0.63x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-16.67%

Cash Flow / Share (Quarterly)$1.22

Price vs S&P 500 (YTD)-1.42%

Gross Margin (TTM)54.64%

Net Profit Margin (TTM)-15.49%

EPS (TTM)$-0.73

10-Day Avg Trading Volume0.10M

EPS Excl Extra (TTM)$-0.73

Revenue Growth (5Y)-19.04%

EPS (Annual)$-0.09

ROI (Annual)-8.45%

Gross Margin (Annual)56.57%

Net Profit Margin (5Y Avg)-20.14%

Cash / Share (Quarterly)$14.67

Revenue Growth QoQ (YoY)7.41%

ROA (Last FY)-5.78%

Revenue Growth TTM (YoY)-21.80%

EBITD / Share (TTM)$-0.14

ROE (5Y Avg)-10.54%

Operating Margin (TTM)-20.14%

Cash Flow / Share (Annual)$0.32

P/B Ratio0.70x

P/B Ratio (Quarterly)0.67x

Net Income / Employee (Annual)$-485,000

EV / Revenue (TTM)1.09x

Net Interest Coverage (TTM)-13.91x

ROA (TTM)-5.08%

EV / EBITDA (TTM)16.37x

EPS Incl Extra (Annual)$-0.09

Current Ratio (Annual)3.34x

Quick Ratio (Quarterly)2.32x

3-Month Avg Trading Volume0.07M

52-Week Price Return12.45%

EV / Free Cash Flow (Annual)26.98x

Revenue / Employee (TTM)$2,088,600

Tangible BV / Share (Quarterly)$20.81

P/S Ratio (Annual)1.46x

Asset Turnover (Annual)0.32x

52-Week High$20.90

Operating Margin (5Y Avg)-22.51%

EPS Excl Extra (Annual)$-0.09

Tangible BV CAGR (5Y)-6.19%

26-Week Price Return-9.48%

Quick Ratio (Annual)2.21x

13-Week Price Return-8.70%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)3.48x

Enterprise Value$181.53M

Revenue / Share Growth (5Y)-20.38%

Asset Turnover (TTM)0.25x

Book Value / Share Growth (5Y)69.05%

Revenue / Employee (Annual)$2,670,600

Inventory Turnover (Annual)0.51x

Pretax Margin (Annual)-16.87%

Cash / Share (Annual)$14.54

3-Month Return Std Dev32.70%

Gross Margin (5Y Avg)64.93%

Net Income / Employee (TTM)$-420,200

ROE (Last FY)-8.45%

Net Interest Coverage (Annual)-14.99x

EPS Basic Excl Extra (Annual)$-0.09

P/FCF (TTM)8.17x

Receivables Turnover (TTM)1.56x

EV / Free Cash Flow (TTM)7.10x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-0.73

Receivables Turnover (Annual)1.72x

ROI (TTM)-7.34%

P/S Ratio (TTM)1.87x

Pretax Margin (5Y Avg)-18.86%

Revenue / Share (Annual)$0.51

Tangible BV / Share (Annual)$21.43

Forward P/E31.59x

Price vs S&P 500 (52W)-10.23%

Year-to-Date Return6.77%

5-Day Price Return6.96%

EPS Normalized (Annual)$-0.09

ROA (5Y Avg)-7.22%

Net Profit Margin (Annual)-18.16%

Month-to-Date Return2.83%

Cash Flow / Share (TTM)$-0.12

EBITD / Share (Annual)$-0.12

Operating Margin (Annual)-23.48%

LT Debt / Equity (Annual)0.00x

P/CF (TTM)12.22x

ROI (5Y Avg)-10.54%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-0.73

P/TBV (Quarterly)0.69x

P/B Ratio (Annual)0.61x

Inventory Turnover (TTM)0.60x

Pretax Margin (TTM)-13.78%

Book Value / Share (Annual)$22.07

Price vs S&P 500 (13W)-17.78%

Beta0.80x

P/FCF (Annual)46.46x

Revenue / Share (TTM)$0.40

ROE (TTM)-7.34%

52-Week Low$12.30

vGradeB

gGradeD

mGradeC

vgmGradeC

Show chart for

Earnings Surprise History

Q1 26-0.09est. 0.09

Analyst Recommendations

Mar 2026

Apr 2026

May 2026

Jun 2026

2.14

Industry Peers — Pharmaceuticals(554)

Symbol	Value Score	Growth Score	Momentum Score	Price
AMRNAmarin Corp Plc	B	D	C	$15.24
LLYEli Lilly & Co.	D	B	B	$1133.00
JNJJohnson & Johnson	D	C	B	$240.87
ABBVABBVIE INC.	D	C	C	$227.73
MRKMerck & Co., Inc.	C	C	B	$119.05
NVSNovartis AG	C	C	B	$153.07
AZNAstraZeneca PLC	C	B	C	$178.75
NVONovo-Nordisk A/S	B	B	B	$43.88
ABTAbbott Laboratories	C	C	D	$88.18
PFEPfizer Inc.	B	C	C	$26.21
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	B	$34.63

About

Amarin Corporation PLC is a pharmaceutical company specializing in cardiovascular health therapeutics. The company commercializes Vascepa, a treatment designed to reduce cardiovascular risk and prevent CV-related mortality. Amarin derives the majority of its revenue from the United States market.